Literature DB >> 3026477

Inhibition of (H+ + K+)-ATPase by omeprazole in isolated gastric vesicles requires proton transport.

P Lorentzon, R Jackson, B Wallmark, G Sachs.   

Abstract

Omeprazole was found to inhibit the (H+ + K+)-ATPase activity in isolated gastric vesicles only when acid was accumulated in the vesicle lumen. The ATPase activity was time- and dose-dependently inhibited in the presence of K+ and valinomycin. Under conditions in which no pH-gradient was generated, i.e., in the presence of K+ alone or NH4+, no effect of omeprazole was found. The degree of inhibition was directly correlated to the amount of inhibitor bound to the preparation. A stoichiometry of 2 mol radiolabelled inhibitor bound per mol phosphoenzyme was found on total inhibition of the K+ plus valinomycin-stimulated activity. This inhibitory action of omeprazole on the ATPase activity could be fully reversed by addition of beta-mercaptoethanol. The inhibition of the proton transport in the (H+ + K+)-ATPase-containing vesicles by omeprazole was also strictly correlated to the amount of bound inhibitor. The stoichiometry of binding at total inhibition of this reaction was found to be 1.4 mol per mol phosphoenzyme. The K+-stimulated p-nitrophenylphosphatase activity was inhibited in parallel with the ATPase activity, whereas the phosphoenzyme levels were affected to a lesser extent by omeprazole. Gel electrophoresis of an omeprazole-inhibited vesicle preparation showed that the radiolabel was mainly found at 94 kDa, the molecular weight of the (H+ + K+)-ATPase catalytic subunit(s).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3026477     DOI: 10.1016/0005-2736(87)90313-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

1.  Cell isolation and genotoxicity assessment in gastric mucosa.

Authors:  D Scott; M Reuben; G Zampighi; G Sachs
Journal:  Dig Dis Sci       Date:  1990-10       Impact factor: 3.199

Review 2.  Gastric H,K-ATPase as a drug target.

Authors:  Jai Moo Shin; George Sachs
Journal:  Dig Dis Sci       Date:  2006-04-28       Impact factor: 3.199

Review 3.  Functional domains of the gastric HK ATPase.

Authors:  G Sachs; K Munson; V N Balaji; D Aures-Fischer; S J Hersey; K Hall
Journal:  J Bioenerg Biomembr       Date:  1989-10       Impact factor: 2.945

4.  Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.

Authors:  Hsiu-Chi Cheng; Bor-Shyang Sheu
Journal:  World J Gastrointest Endosc       Date:  2011-03-16

Review 5.  Gastric H+,K(+)-ATPase as a therapeutic target in peptic ulcer disease.

Authors:  G Sachs; K Munson; K Hall; S J Hersey
Journal:  Dig Dis Sci       Date:  1990-12       Impact factor: 3.199

Review 6.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

7.  Antileishmanial activity of the antiulcer agent omeprazole.

Authors:  Suping Jiang; Juliana Meadows; Steven A Anderson; Antony J Mukkada
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 8.  Structural aspects of the gastric H,K-ATPase.

Authors:  G Sachs; M Besancon; J M Shin; F Mercier; K Munson; S Hersey
Journal:  J Bioenerg Biomembr       Date:  1992-06       Impact factor: 2.945

Review 9.  Pharmacological aspects of acid secretion.

Authors:  B I Hirschowitz; D Keeling; M Lewin; S Okabe; M Parsons; K Sewing; B Wallmark; G Sachs
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

10.  Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole.

Authors:  Angela Abelö; Björn Holstein; Ulf G Eriksson; Johan Gabrielsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.